Ophthalmos Research team has discovered a novel therapy for vision improvement in patients with Stargardt disease. It is one of the most common forms of macular dystrophy and to date no treatment has provided evidence of disease regression. The published paper shows how fatty acids reduced the accumulation of lipofuscin granules and A2E levels and decreased C3 level, in the retina of animal model of Stargardt disease. It also demonstrated a protective effect against photoreceptors which confirms Ophthalmos Institute observational studies for vision improvement in patients with Stargardt disease.
Link : click HERE for the publication
